Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.

Clover Biopharmaceuticals, Ltd.

Clover Biopharmaceuticals is a global commercial-stage biotechnology company that develops innovative vaccines. Self-described to be committed to improving health worldwide.

Clover Biopharmaceuticals

Clover Biopharmaceuticals | 7,293 followers on LinkedIn. Unleashing the power of innovative vaccines to save lives and improve health around the world | Founded in 2007, we are a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing, and commercial capabilities as well as strong partnerships with organizations globally, we have developed a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. As we focus on delivering vaccines for a healthier world, we remain steadfast in our dedication to both scientific innovation and equitable access.

Chief Financial Officer and Chief Strategy Officer at Tarsus Pharmaceuticals

Jeff Farrow

Senior Director Clinical Operation at Clover Biopharmaceuticals

Aurore Dujardin

Founder， Chairman of the Board of Clover Biopharmaceuticals

Peng Liang

Building Around Talent

Oscar Shen

Attend Europe’s Largest Vaccine R&D Conference！ ☘️☘️☘️ WE ARE ATTENDING AND PRESENTING! ☘️☘️☘️ 📍WORLD VACCINE CONGRESS MEET YOU THERE! #WVC #CLOVER #Vaccine #RSV

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue					39.26M -
cost of revenue					1.71B -
gross profit					-1.67B -
selling and marketing expenses					54.77M -
general and administrative expenses	17.04M -	76.43M 348.66%	345.71M 352.33%	113.07M 67.29%	198.82M 75.83%
selling general and administrative expenses	17.04M -	76.43M 348.66%	345.71M 352.33%	113.07M 67.29%	253.58M 124.27%
research and development expenses	45.80M -	228.22M 398.31%	1.83B 700.24%	1.47B 19.77%	649.88M 55.65%
other expenses	-15.91M -	-20.36M 27.97%	-14.23M 30.12%	282.76M 2,087.61%
cost and expenses	46.92M -	284.29M 505.84%	2.16B 659.01%	1.86B 13.75%	3.25B 74.60%
operating expenses	46.92M -	284.29M 505.84%	2.16B 659.01%	1.86B 13.75%	1.54B 17.40%
interest expense	10.33M -	2.97M 71.23%	2.52M 15.24%	5.93M 135.32%
ebitda	-35.85M -	-904.14M 2,421.73%	-5.99B 562.43%	-2.39B 60.16%	-2.58B 8.14%
operating income	-38.25M -	-909.92M 2,278.83%	-6.01B 561.01%	-2.45B 59.33%	-2.61B 6.67%
depreciation and amortization	2.40M -	5.78M 141.30%	25.39M 338.95%	60.09M 136.69%	28.98M 51.78%
total other income expenses net	-10.33M -	-2.97M 71.23%	-1.61M 45.78%	-5.70M 253.66%	2.47B 43,441.33%
income before tax	-48.58M -	-912.90M 1,779.05%	-6.02B 559.03%	-2.45B 59.25%	-138.54M 94.35%
income tax expense	10.33M -	2.97M 71.23%	1.61M 45.78%	-229K 114.21%
net income	-58.91M -	-915.87M 1,454.56%	-6.02B 557.07%	-2.45B 59.26%	-138.54M 94.35%
weighted average shs out	1.16B -	1.16B 0%	462.12M 60.10%	1.10B 138.49%	1.24B 12.83%
weighted average shs out dil	1.16B -	1.16B 0%	462.12M 60.10%	1.10B 138.49%	1.24B 12.83%
eps	-0.05 -	-0.79 1,452.06%	-13.02 1,548.10%	-2.22 82.95%	-0.11 95.05%
epsdiluted	-0.05 -	-0.79 1,452.06%	-13.02 1,548.10%	-2.22 82.95%	-0.11 95.05%

2197

COM:CLOVERBIOPHARMA

Clover Biopharmaceuticals

Last Close

0.30

21/11 07:54

Market Cap

415.27M

Beta: -

Volume Today

677K

Avg: -

Preview